Combination of cisplatin, epirubicin, and cyclophosphamide (PEC regimen) in advanced or recurrent endometrial cancer: a retrospective clinical study.

Abstract

The combination of cisplatin (50 mg/m2), epirubicin (60 mg/m2), and cyclophosphamide (600 mg/m2) (PEC regimen) was given every 4 weeks to 19 patients with advanced (n.2) or recurrent (n.17) endometrial cancer. The median number of cycles delivered to each patient was 5 (range, 2-8). All patients were evaluable for toxicity and 16 for response. Two (12.5… (More)

Topics

Cite this paper

@article{Gadducci1999CombinationOC, title={Combination of cisplatin, epirubicin, and cyclophosphamide (PEC regimen) in advanced or recurrent endometrial cancer: a retrospective clinical study.}, author={Angiolo Gadducci and Antonella Romanini and Stefania Cosio and Antonio Fanucchi and L. Tanganelli and Benedetta Ciampi and A. R. Genazzani}, journal={Anticancer research}, year={1999}, volume={19 3B}, pages={2253-6} }